

May 11, 2020
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses)
Issued by way of Third Party Allotment

TOKYO, Japan, May 11, 2020—Symbio Pharmaceuticals Limited announces the large volume exercise of the 50th Stock Acquisition Rights, issued and allotted to EVO FUND on March 16, 2020, on May 11, 2020, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 50 th Stock Acquisition Rights
(2)	Number of issued shares from the previous disclosure	1,210,000 Shares
(3)	Number of stock acquisition rights being exercised from the previous disclosure and the ratio to the entire issue	1,210,000 Units (Ratio to the total number of stock acquisition rights issued 7,000,000 units : 17.3%)
(4)	Number of unexercised stock acquisition rights as of the previous disclosure	2,300,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	1,090,000 Units

(6) Exercise status from the previous disclosure

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
May 11 (Mon)	1,210,000	-	308	1,210,000

※Number of issued shares at the end of the previous month : 31,268,756 shares [of which 22,018 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)” published on February 27, 2020.